CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,088 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04413539
NCT04413539N/ACompleted

Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living with Sickle- Cell Disease in France

Argo Sante·observational·Posted Jun 4, 2020·Updated Jan 29, 2025

In Brief

An observational study for Sickle-cell Disease (SCD). Completed, enrolled 1,088 participants across 1 site.

Detailed Summary

Sickle cell disease (SCD) is the most common genetic disease in France. Its consequences on patient's life-course and quality of life need to be precisely identified among French patients and their family to be able to improve patients care according to their specific needs. The aim of the study is to accurately describe the impact of SCD on quality of life of patients living in France, or their family (for minor patients). The consequences of the disease on professional life, education and material condition of patients or their parents will be described by the patients themselves.

Study Details

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 4, 2020
Enrollment StartJun 2, 2020
Primary CompletionApr 27, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago